At a glance
ClinicalIndex Comparison RecordPhase 4Unknown· 4,005 enrolled
Drug / intervention
Clopidogrel +1 moredrug
Likely dose
Clopidogrel 75mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent
In Brief
A Phase 4 clinical trial evaluating Clopidogrel and Placebo for Coronary Artery Disease. Targeting 4,005 participants across 40 sites in 13 countries.
Detailed Summary
The purpose of this study is to determine whether a 6 month duration of clopidogrel therapy after DES implantation is not inferior to that of a 12 month therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesAlbania, Austria, Belgium, China, Denmark, Germany, Ireland, Italy, Japan, Netherlands, New Zealand, Switzerland, United States
Collaborators--
Timeline
Phase 4UnknownOverdue
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartSep 2008
Primary CompletionNov 2014
TodayJul 2026
First PostedApr 18, 2008
Enrollment StartSep 1, 2008
Primary CompletionNov 1, 2014
TodayJul 1, 2026
Enrollment to primary: 6.2 yearsPosted 18.2 years ago
Interventions
Clopidogreldrug
Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day
Placebodrug
Patients randomized in this group will receive placebo for 6 months.